1. Home
  2. Our Firm
  3. News
  4. Dana Flanders Joins Guggenheim Securities as Therapeutics Analyst

Our Firm

March 20, 2019

Dana Flanders Joins Guggenheim Securities as Therapeutics Analyst

NEW YORK – Guggenheim Securities, the investment banking and capital markets division of Guggenheim Partners, announced today that Dana Flanders will join the firm in May as a Director in a planned expansion of the Healthcare research team. Mr. Flanders will focus on the coverage of specialty pharmaceutical and biotech companies, working closely with the firm’s growing therapeutics group.

Mr. Flanders will join Guggenheim most recently from Goldman Sachs, where he was a senior equity research analyst and Vice President covering specialty and small-to-mid-cap biopharmaceutical companies. Prior to Goldman Sachs, he covered specialty pharmaceutical companies as an equity research analyst at J.P. Morgan. Previously, he worked at Canaccord Genuity covering specialty pharmaceuticals.

“Dana will be an excellent addition to our research team,” said Stefano Natella, Co-Head of Equities at Guggenheim Securities. “His expertise in the specialty pharmaceutical sector complements the deep roster of talent we have assembled in the healthcare space. I look forward to his future successes at Guggenheim.”

Over the past two years, Guggenheim has significantly expanded its Healthcare research team, which now includes analysts Seamus Fernandez, Michael Schmidt, Whitney Ijem, Yatin Suneja, Etzer Darout, Adnan Butt, Glen Santangelo, Dave Westenberg, and Chris Pasquale.

Mr. Flanders is a CFA Charterholder and received his B.A. from Cornell University. He will be based in Guggenheim’s New York office.


About Guggenheim Securities

Guggenheim Securities is the investment banking and capital markets business of Guggenheim Partners, a global investment and advisory firm. Guggenheim Securities offers services that fall into four broad categories: Advisory, Financing, Sales and Trading, and Research. Guggenheim Securities is headquartered in New York, with additional offices in Chicago, Boston, Atlanta, San Francisco, and Houston. For more information, please contact us at GSinfo@GuggenheimPartners.com or 212.518.9200.


About Guggenheim Partners

Guggenheim Partners is a global investment and advisory firm with more than $265 billion1 in assets under management. Across our three primary businesses of investment management, investment banking, and insurance services, we have a track record of delivering results through innovative solutions. With over 2,400 professionals based in offices around the world, our commitment is to advance the strategic interests of our clients and to deliver long-term results with excellence and integrity. We invite you to learn more about our expertise and values by visiting GuggenheimPartners.com and following us on Twitter at twitter.com/guggenheimptnrs.


Media Contact

Ellen Cunningham
Guggenheim Partners
212.518.9578
Ellen.N.Cunningham@GuggenheimPartners.com

 

1Assets under management are as of 12.31.2018 and include consulting services for clients whose assets are valued at approximately $67bn.



November 09, 2020

Guggenheim Securities Hires David Levin to Expand Equity Capital Markets

NEW YORK, NY –  Guggenheim Securities, the investment banking and capital markets division of Guggenheim Partners, announced today that David Levin will join the firm as a Senior Managing Director in Equity Capital Markets, focusing on providing clients with equity and equity-linked financing solutions through the public and alternative equity capital markets.

Read More

October 22, 2020

Guggenheim Securities Hires Joe Niemiec to Expand Middle Market Investment Banking Practice

NEW YORK, NY – Guggenheim Securities, the investment banking and capital markets division of Guggenheim Partners, announced today that Joe Niemiec has joined the firm as a Senior Managing Director to expand its middle market investment banking coverage and to focus on advising companies in the services and industrials sectors.

Read More

October 05, 2020

Debjit Chattopadhyay Joins Guggenheim Securities as Senior Biotech Analyst

NEW YORK, NY – Guggenheim Securities, the investment banking and capital markets division of Guggenheim Partners, announced today that Debjit Chattopadhyay will join the firm in December as a Managing Director and Senior Biotech Analyst as part of the Healthcare Equity Research team. Dr. Chattopadhyay’s research focus will be gene therapy and rare diseases.

Read More



© 2020 Guggenheim Partners, LLC. All rights reserved. Guggenheim, Guggenheim Partners and Innovative Solutions. Enduring Values. are registered trademarks of Guggenheim Capital, LLC.